Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 1/2 1Phase 1 1

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3Breast 1

Conditions

Stomach Neoplasms 3Breast Neoplasms 2Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Recurrence 1Ovarian Neoplasms 1Neoplasm Metastasis 1Hematologic Neoplasms 1HER2-positive Breast Cancer 1Esophageal Neoplasms 1Cholangiocarcinoma 1Carcinoma, Non-Small-Cell Lung 1Breast Cancer Metastatic 1

Interventions

Capecitabine 77pembrolizumab 70Oxaliplatin 68Cisplatin 56Fluorouracil 52Paclitaxel 41Trastuzumab 37Nivolumab 35Leucovorin 27Docetaxel 27Irinotecan 22Ramucirumab 20Gemcitabine 15Bevacizumab 15S 1 (combination) 14Carboplatin 13atezolizumab 12apatinib 12fludarabine 11Cyclophosphamide 11tislelizumab 10Drug Therapy 10Injections 8130-nm albumin-bound paclitaxel 8trastuzumab deruxtecan 7durvalumab 7Ipilimumab 7Folfox protocol 7Albumin-Bound Paclitaxel 7titanium silicide 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Stomach Neoplasms × margetuximab × Clear all
NCT04082364 2025-06-08

MAHOGANY

MacroGenics

Phase 2/3 Completed
82 enrolled 22 charts
Gastrointestinal

Stomach Neoplasms

NCT02689284 2025-03-17

Combination Margetuximab and Pembrolizumab for Advanced, Metastatic HER2(+) Gastric or Gastroesophageal Junction Cancer

MacroGenics

Phase 1/2 Completed
95 enrolled 26 charts
Gastrointestinal

Esophageal Neoplasms, Stomach Neoplasms

NCT01148849 2025-02-26

Safety Study of MGAH22 in HER2-positive Carcinomas

MacroGenics

Phase 1 Completed
66 enrolled
BreastGastrointestinal

Breast Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡